You are not logged in
Visit our Twitter
Visit our LinkedIn
POST-MEETING-SURVEY-Exploring the current gastroesophageal cancer treatment landscape and near-future developments
If you wish to view the details for the meeting, then please click the button.
Back to the Meeting Details
What does the current evidence suggest for localised gastroesophageal cancer patients with dMMR/MSI high (deficient mismatch repair / high microsatellite instability)?
Patients have higher 5-year overall survival (OS) and do not benefit from perioperative and/or adjuvant chemotherapy
Patients have lower 5-year overall survival (OS) and benefit from perioperative and/or adjuvant chemotherapy
5- year overall survival does not differ, but patients benefit from perioperative and/or adjuvant chemotherapy
Overall survival does not differ, but patients may benefit from tumour resection upfront
What is the significance of ctDNA (circulating tumour DNA) presence in early gastric cancer after curative intent surgery?
High recurrence rate and worse survival
Lower recurrence rate and better survival
Lower recurrence rate but worse survival
CtDNA does not have any significance in this case
Which of the following tumour markers are predictive of immune checkpoint blockade (ICB) benefit in localised gastroesophageal cancer?
TMB-H (tumour mutational burden-high)
Both TMB-H and dMMR/MSI-H
None of the above
Which subset of gastroesophageal cancer patients show intrinsic resistance with trastuzumab treatment?
Patients with ERBB2 amplification
Patients with who lack ERBB2 amplification
Patients with co-mutations of the RTK/RAS/PI3K pathway
Second and third option
On a scale of 1 to 5, how valuable (with 5 as extremely valuable) did you find this Experts Knowledge Share on gastroesophageal cancer?
On a scale of 1 to 5, how strongly do you agree that your knowledge of gastroesophageal cancer has improved as a result of participating in this programme (with 5 as very strongly agree)?
Are you planning to change your clinical practice based upon you participation in this Experts Knowledge Share?
No, the content confirms my current practice
No, I am unable to change my current practice
On average, how many patients with gastroesophageal cancer do you see in 1 year?
More than 20
On a scale of 1-5 (with 5 as very balanced and unbiased), to what extent do you feel this Experts Knowledge Share was balanced and unbiased?
Do you have any other comments or feedback?
We are pleased to offer an honorarium payment for participation in this interactive meeting
COR2ED develops and implements high quality Independent Medical Education programmes to help improve the health of patients globally.
Disclaimer: The material and content contained in the website engage.cor2ed.com is for healthcare professionals only. Although every effort is made to ensure that the material within this website is accurate and timely, it is provided for informational and educational purposes only. The information provided is not intended as a substitute for medical professional help, advice, diagnosis or treatment and may not be applicable to every case or country.
© Copyright 2021 | All Rights Reserved